NasdaqCM:ONCYBiotechs
Oncolytics Biotech’s Pelareorep Data Reshapes Colorectal Cancer And Investor Outlook
Oncolytics Biotech reported new durability and response data for its pelareorep therapy in RAS-mutant MSS metastatic colorectal cancer.
The pelareorep-based regimen outperformed historical benchmarks in second-line treatment, with longer median duration of response and higher objective response rates.
The company has initiated enrollment in a Phase 2 randomized study and is in active discussions with the FDA on a potential accelerated approval pathway.
For investors watching NasdaqCM:ONCY,...